Biostar Pharmaceuticals Announces Receipt of Additional Delisting Determination Letter from Nasdaq
23 Août 2018 - 2:51PM
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (the “Company”), a
PRC-based manufacturer and marketer of pharmaceutical and health
supplement products in China, announced today that on August
16, 2018, it received a notification letter from Nasdaq Listing
Qualifications (“Nasdaq”) advising the Company that, since it had
not filed its Quarterly Report on Form 10-Q for the second quarter
ended June 30, 2018, this matter serves as an additional basis for
delisting the Company’s securities from The Nasdaq Stock Market.
Previously, on April 19, 2018 and May 23, 2018,
the Company received notification letters from Nasdaq advising the
Company that, since it had not filed its Annual Report on Form 10-K
for the fiscal year ended December 31, 2017 and its Quarterly
Report on Form 10-Q for the fiscal quarter ended March 31, 2018,
the Company was not in compliance with Nasdaq Listing Rules.
On July 19, 2018, the Company received a
delisting determination letter from the Nasdaq advising the Company
that following review of the Company’s plan of compliance, the
Nasdaq staff determined to delist the Company’s common stock from
the Nasdaq Capital Market.
On July 26, 2018, the Company requested a
hearing before the Nasdaq Hearings Panel (the "Panel") to appeal
the delisting determination from the Nasdaq staff. On August
10, 2018, the Company was granted an extended stay as to the
suspension of the Company's common stock from trading by the Panel
until the Company's scheduled hearing before the Panel on September
13, 2018 and issuance of a final Panel decision.
As a result of the latest Form
10-Q filing delinquency, the Panel will consider this matter
in rendering a determination regarding the Company's continued
listing on The Nasdaq Capital Market. Pursuant to Listing Rule
5810(d), the Company plans to present its views with respect to
this additional deficiency at the hearing.
The Company is working assiduously to complete
its delinquent filings with SEC and to regain compliance with the
Rule as soon as possible.
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly owned
subsidiary and controlled affiliate in China, develops,
manufactures, and markets pharmaceutical and health supplement
products for a variety of diseases and conditions. For more
information please
visit: http://www.biostarpharmaceuticals.com.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties.
Such forward-looking statements include statements about the
Company’s receipt of Nasdaq’s deficiency letters and plan to regain
compliance described herein. Actual events or results may
differ materially from the Company’s expectations. Factors
that could cause actual results to differ materially from those
stated or implied by the Company’s forward-looking statements are
disclosed in its filings with the Securities and Exchange
Commission. These forward-looking statements represent the
Company’s judgment as of the time of this release. The
Company disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Investor Relations Contact
Please send questions or comments to:
Biostar Pharmaceuticals, Inc.
Investor Relations Coordinator
+86-29-3368-6638
office@aoxing-group.com
http://www.biostarpharmaceuticals.com
Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024